Core-002 - Non-Human Primate Core

Core-002 - 非人类灵长类核心

• 批准号: 10557875
• 负责人: Christopher Yeh Chen
• 金额: $ 42.33万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-01 至 2027-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10557875
• 关键词: Affect; Animal Euthanasia; Animal Model; Animals; Antibodies; Antibody Response; Antigens; Awareness; Biomedical Research; Blood; Blood specimen; Breeding; Callithrix; Chronic; Chronic Hepatitis C; Clinical; Collaborations; Collection; Complex; Computing Methodologies; Data; Diagnosis; Experimental Designs; Genetic; Goals; Hepatitis C Vaccine; Hepatitis C virus; Human; Immune; Immune response; Immunization; Individual; Institution; Laboratories; Liver Cirrhosis; Macaca mulatta; Malignant neoplasm of liver; Modeling; Papio; Parents; Persons; Preclinical Testing; Predictive Value; Primates; Procedures; Recording of previous events; Regimen; Research; Research Institute; Research Personnel; Research Project Grants; Resources; Safety; Sampling; Site; Structure; Testing; Texas; Tissue Sample; Tissues; Toxic effect; Training; Vaccinated; Vaccination; Vaccine Antigen; Vaccine Research; Vaccines; Viral Antigens; biobank; chronic infection; design; experimental study; immunogenicity; member; nanoparticle; nonhuman primate; novel; novel vaccines; prevent; programs; protocol development; rational design; self assembly; vaccine candidate

Summary Chronic hepatitis C virus (HCV) infection affects an estimated 71 million people worldwide. Chronic HCV infection frequently leads to liver cirrhosis and predisposes infected individuals to liver cancer. Approximately, 400,000 die from HCV-related complications a year. While a cure for HCV has recently been developed, access to and affordability of this treatment is limited. Furthermore, less than 20% of chronically infected individuals are aware of their diagnosis. Therefore, to eliminate HCV, a vaccine is still urgently needed. Because of the genetic variability of the HCV, to date HCV vaccines that have been tested clinically have not been successful at preventing chronic infection. This study takes advantage of recent structural data of HCV antigen complexes, computational methods to optimize antigen structure presentation, multivalent presentation of those antigens on self-assembling nanoparticles, and preclinical testing in a nonhuman primate model that has demonstrated strong predictive value of human antibody responses. Core C: NHP, based at the Southwest National Primate Research Center, will evaluate the immunogenicity of rationally designed HCV vaccine antigens and nanoparticles using a non-human primate (NHP) model, rhesus macaques, and collect blood and tissue samples to enable in-depth analysis of the immune responses elicited by the vaccine antigens in this P01 research program.

总结